Wayrilz
What Wayrilz is used for
Wayrilz is indicated for the treatment of immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (see section 5.1)
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Wayrilz
- Active substance
- rilzabrutinib
- Disease area
- Purpura, Thrombocytopenic, Idiopathic
- Medicine group
- Not assigned yet
- ATC code
- Not yet assigned
- Marketing authorisation holder
- Sanofi B.V.
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Wayrilz
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Wayrilz used for?
Wayrilz is indicated for the treatment of immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (see section 5.1)
What is the active substance in Wayrilz?
Wayrilz contains rilzabrutinib.
Who makes Wayrilz?
The EU marketing authorisation holder is Sanofi B.V..
Is Wayrilz an orphan medicine?
Yes. Wayrilz is designated an orphan medicine in the EU, for a rare disease (Purpura, Thrombocytopenic, Idiopathic).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU